多发性硬化症药物市场规模、份额和成长分析（按类型、给药途径、分销管道和地区）- 产业预测 2025-2032

2023 年多发性硬化症治疗市场规模价值 284 亿美元，预计将从 2024 年的 296.2 亿美元成长到 2032 年的 414.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.3%。

由于疾病负担不断增加和对有效治疗的需求不断增加，多发性硬化症 (MS) 市场预计将经历显着增长。随着多发性硬化症发病率的上升，大型製药企业正在加强研发力度，开发创新治疗方法，创造丰厚的商机。值得注意的是，Adamas Pharmaceuticals Inc. 宣布临床实验药物 ADS-5102 的 3 期试验取得了令人欣喜的结果。此外，政府旨在增加产品发布和改善治疗机会的措施可能会进一步支持市场扩张。家用鼻内抗 CD3 单株抗体等新型疗法的推出体现了该产业对推进 MS 治疗方案的决心。总体而言，预计美国MS 药物市场在未来的预测期内将保持持续的复合年增长率。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

多发性硬化症药物市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 免疫调节药物
• 干扰素
• 免疫抑制剂
• 其他类型

多发性硬化症药物市场规模（依给药途径和复合年增长率） (2025-2032)

• 市场概况
• 口服
• 肠外
• 其他的

多发性硬化症药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 网路药局
• 零售药局
• 其他分销管道

多发性硬化症药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Biogen Inc.（United States）
• Roche Holdings AG（Switzerland）
• Novartis AG（Switzerland）
• Sanofi SA（France）
• Merck & Co., Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• AbbVie Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• Celgene Corporation（United States）
• Bristol-Myers Squibb Company（United States）
• Mitsubishi Tanabe Pharma Corporation（Japan）
• Biogen Idec International GmbH（Switzerland）
• Genzyme Corporation（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Merck KGaA（Germany）
• Mylan NV（United States）

结论和建议

Multiple Sclerosis Drugs Market size was valued at USD 28.4 billion in 2023 and is poised to grow from USD 29.62 billion in 2024 to USD 41.48 billion by 2032, growing at a CAGR of 4.3% during the forecast period (2025-2032).

The multiple sclerosis (MS) market is poised for significant growth due to an increasing disease burden and rising demand for effective therapeutics. As the prevalence of MS grows, major pharmaceutical companies are intensifying their R&D efforts to develop innovative treatments, creating lucrative opportunities. Notably, Adamas Pharmaceuticals Inc. has announced promising results from its phase 3 trial of ADS-5102, an investigational agent for MS. Additionally, product launches and government initiatives aimed at improving treatment accessibility will further support market expansion. The introduction of novel therapies, such as an intranasal anti-CD3 monoclonal antibody for at-home use, exemplifies the industry's commitment to advancing MS treatment options. Overall, the US MS drugs market is expected to maintain a sustainable CAGR in the coming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Sclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Sclerosis Drugs Market Segments Analysis

Global Multiple Sclerosis Drugs Market is segmented by Type, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Immunomodulators, Interferons, Immunosuppressants and Other types. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Multiple Sclerosis Drugs Market

The escalating prevalence of multiple sclerosis (MS) worldwide significantly propels the growth of the multiple sclerosis drugs market. According to the National Multiple Sclerosis Society, approximately 2.8 million individuals globally are affected by MS, a figure that is on the rise, particularly in more developed regions. This increasing patient population underscores the urgent need for advanced therapies aimed at managing disease progression effectively. As the demand for innovative treatment options grows, pharmaceutical companies are driven to invest in research and development to cater to the evolving needs of patients suffering from MS, further stimulating the market's expansion.

Restraints in the Multiple Sclerosis Drugs Market

The high cost associated with treatments for multiple sclerosis presents a significant obstacle to market growth. Many disease-modifying therapies, particularly those related to chemotherapy and oral medications, are priced at premium levels, rendering them inaccessible for patients lacking comprehensive insurance coverage. This financial strain is especially severe in both high-income and low-income countries where health systems may not possess the necessary resources to provide or support these expensive treatments effectively. As a result, the affordability issue creates a substantial barrier to accessing vital therapies, ultimately hindering market potential and patient care in the multiple sclerosis treatment landscape.

Market Trends of the Multiple Sclerosis Drugs Market

In the Multiple Sclerosis (MS) drugs market, a significant trend is the acceleration towards personalized medicine and biomarker-based therapies. Advances in genetics and molecular biology are facilitating the identification of specific biomarkers that predict disease progression and patient response to treatment. This shift is fostering the creation of tailored therapeutic solutions designed to optimize efficacy and minimize side effects for individuals with MS. As healthcare providers increasingly emphasize personalized treatment approaches, pharmaceutical companies are prioritizing research and development of targeted therapies, thereby reshaping the landscape of MS treatment and fostering improved outcomes and quality of life for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• Immunomodulators
• Interferons
• Immunosuppressants
• Other types

Global Multiple Sclerosis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Global Multiple Sclerosis Drugs Market Size & CAGR (2025-2032)

• North America (Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Idec International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations